vs
Side-by-side financial comparison of NCR Atleos Corp (NATL) and Insulet Corporation (PODD). Click either name above to swap in a different company.
NCR Atleos Corp is the larger business by last-quarter revenue ($1.2B vs $761.7M, roughly 1.5× Insulet Corporation). Insulet Corporation runs the higher net margin — 12.0% vs 7.2%, a 4.8% gap on every dollar of revenue. On growth, Insulet Corporation posted the faster year-over-year revenue change (33.9% vs 4.0%). NCR Atleos Corp produced more free cash flow last quarter ($194.0M vs $89.5M). Over the past eight quarters, Insulet Corporation's revenue compounded faster (24.9% CAGR vs 4.9%).
NCR Voyix Corporation, previously known as NCR Corporation and National Cash Register, is a global software, consulting and technology company providing several professional services and electronic products. It manufactured self-service kiosks, point-of-sale terminals, automated teller machines, check processing systems, and barcode scanners.
An insulin pump is a medical device used for the administration of insulin in the treatment of diabetes mellitus, also known as continuous subcutaneous insulin therapy . The device configuration may vary depending on design. A traditional pump includes:the pump a disposable reservoir for insulin a disposable infusion set, including a cannula for subcutaneous insertion and a tubing system to connect the insulin reservoir to the cannula.
NATL vs PODD — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $1.2B | $761.7M |
| Net Profit | $83.0M | $91.1M |
| Gross Margin | — | 69.5% |
| Operating Margin | 13.5% | 16.0% |
| Net Margin | 7.2% | 12.0% |
| Revenue YoY | 4.0% | 33.9% |
| Net Profit YoY | 102.4% | 157.3% |
| EPS (diluted) | $1.09 | $1.30 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $761.7M | ||
| Q4 25 | $1.2B | $783.7M | ||
| Q3 25 | $1.1B | $706.3M | ||
| Q2 25 | $1.1B | $649.1M | ||
| Q1 25 | $979.0M | $569.0M | ||
| Q4 24 | $1.1B | $597.5M | ||
| Q3 24 | $1.1B | $543.9M | ||
| Q2 24 | $1.1B | $488.5M |
| Q1 26 | — | $91.1M | ||
| Q4 25 | $83.0M | $101.6M | ||
| Q3 25 | $26.0M | $87.6M | ||
| Q2 25 | $39.0M | $22.5M | ||
| Q1 25 | $14.0M | $35.4M | ||
| Q4 24 | $41.0M | $100.7M | ||
| Q3 24 | $21.0M | $77.5M | ||
| Q2 24 | $27.0M | $188.6M |
| Q1 26 | — | 69.5% | ||
| Q4 25 | — | 72.6% | ||
| Q3 25 | — | 72.2% | ||
| Q2 25 | — | 69.7% | ||
| Q1 25 | — | 71.9% | ||
| Q4 24 | — | 72.1% | ||
| Q3 24 | — | 69.3% | ||
| Q2 24 | — | 67.7% |
| Q1 26 | — | 16.0% | ||
| Q4 25 | 13.5% | 18.7% | ||
| Q3 25 | 9.8% | 16.7% | ||
| Q2 25 | 10.8% | 18.7% | ||
| Q1 25 | 9.5% | 15.6% | ||
| Q4 24 | 13.4% | 18.3% | ||
| Q3 24 | 10.6% | 16.2% | ||
| Q2 24 | 9.8% | 11.2% |
| Q1 26 | — | 12.0% | ||
| Q4 25 | 7.2% | 13.0% | ||
| Q3 25 | 2.3% | 12.4% | ||
| Q2 25 | 3.5% | 3.5% | ||
| Q1 25 | 1.4% | 6.2% | ||
| Q4 24 | 3.7% | 16.9% | ||
| Q3 24 | 2.0% | 14.2% | ||
| Q2 24 | 2.5% | 38.6% |
| Q1 26 | — | $1.30 | ||
| Q4 25 | $1.09 | $1.42 | ||
| Q3 25 | $0.34 | $1.24 | ||
| Q2 25 | $0.52 | $0.32 | ||
| Q1 25 | $0.19 | $0.50 | ||
| Q4 24 | $0.56 | $1.38 | ||
| Q3 24 | $0.28 | $1.08 | ||
| Q2 24 | $0.37 | $2.59 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $456.0M | $480.4M |
| Total DebtLower is stronger | $2.7B | $18.6M |
| Stockholders' EquityBook value | $403.0M | $1.3B |
| Total Assets | $5.7B | $3.0B |
| Debt / EquityLower = less leverage | 6.63× | 0.01× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $480.4M | ||
| Q4 25 | $456.0M | — | ||
| Q3 25 | $412.0M | — | ||
| Q2 25 | $357.0M | — | ||
| Q1 25 | $352.0M | — | ||
| Q4 24 | $419.0M | — | ||
| Q3 24 | $395.0M | — | ||
| Q2 24 | $374.0M | — |
| Q1 26 | — | $18.6M | ||
| Q4 25 | $2.7B | $930.8M | ||
| Q3 25 | $2.8B | $934.9M | ||
| Q2 25 | $2.8B | $939.0M | ||
| Q1 25 | — | $1.6B | ||
| Q4 24 | $2.9B | $1.3B | ||
| Q3 24 | — | $1.4B | ||
| Q2 24 | — | $1.4B |
| Q1 26 | — | $1.3B | ||
| Q4 25 | $403.0M | $1.5B | ||
| Q3 25 | $330.0M | $1.4B | ||
| Q2 25 | $350.0M | $1.5B | ||
| Q1 25 | $275.0M | $1.3B | ||
| Q4 24 | $219.0M | $1.2B | ||
| Q3 24 | $264.0M | $1.1B | ||
| Q2 24 | $250.0M | $998.4M |
| Q1 26 | — | $3.0B | ||
| Q4 25 | $5.7B | $3.2B | ||
| Q3 25 | $5.7B | $3.0B | ||
| Q2 25 | $5.8B | $3.5B | ||
| Q1 25 | $5.7B | $3.5B | ||
| Q4 24 | $5.5B | $3.1B | ||
| Q3 24 | $5.7B | $3.0B | ||
| Q2 24 | $5.8B | $2.9B |
| Q1 26 | — | 0.01× | ||
| Q4 25 | 6.63× | 0.61× | ||
| Q3 25 | 8.45× | 0.68× | ||
| Q2 25 | 8.05× | 0.64× | ||
| Q1 25 | — | 1.21× | ||
| Q4 24 | 13.05× | 1.07× | ||
| Q3 24 | — | 1.21× | ||
| Q2 24 | — | 1.36× |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $231.0M | $113.8M |
| Free Cash FlowOCF − Capex | $194.0M | $89.5M |
| FCF MarginFCF / Revenue | 16.8% | 11.8% |
| Capex IntensityCapex / Revenue | 3.2% | 3.2% |
| Cash ConversionOCF / Net Profit | 2.78× | 1.25× |
| TTM Free Cash FlowTrailing 4 quarters | $239.0M | $415.7M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $113.8M | ||
| Q4 25 | $231.0M | $183.3M | ||
| Q3 25 | $25.0M | $125.7M | ||
| Q2 25 | $-23.0M | $196.5M | ||
| Q1 25 | $123.0M | $63.8M | ||
| Q4 24 | $80.0M | $147.7M | ||
| Q3 24 | $107.0M | $98.5M | ||
| Q2 24 | $9.0M | $96.5M |
| Q1 26 | — | $89.5M | ||
| Q4 25 | $194.0M | $48.2M | ||
| Q3 25 | $-5.0M | $100.1M | ||
| Q2 25 | $-44.0M | $177.9M | ||
| Q1 25 | $94.0M | $51.5M | ||
| Q4 24 | $62.0M | $94.1M | ||
| Q3 24 | $85.0M | $71.8M | ||
| Q2 24 | $-14.0M | $74.0M |
| Q1 26 | — | 11.8% | ||
| Q4 25 | 16.8% | 6.2% | ||
| Q3 25 | -0.4% | 14.2% | ||
| Q2 25 | -4.0% | 27.4% | ||
| Q1 25 | 9.6% | 9.1% | ||
| Q4 24 | 5.6% | 15.7% | ||
| Q3 24 | 7.9% | 13.2% | ||
| Q2 24 | -1.3% | 15.1% |
| Q1 26 | — | 3.2% | ||
| Q4 25 | 3.2% | 17.2% | ||
| Q3 25 | 2.7% | 3.6% | ||
| Q2 25 | 1.9% | 2.9% | ||
| Q1 25 | 3.0% | 2.2% | ||
| Q4 24 | 1.6% | 9.0% | ||
| Q3 24 | 2.1% | 4.9% | ||
| Q2 24 | 2.1% | 4.6% |
| Q1 26 | — | 1.25× | ||
| Q4 25 | 2.78× | 1.80× | ||
| Q3 25 | 0.96× | 1.43× | ||
| Q2 25 | -0.59× | 8.73× | ||
| Q1 25 | 8.79× | 1.80× | ||
| Q4 24 | 1.95× | 1.47× | ||
| Q3 24 | 5.10× | 1.27× | ||
| Q2 24 | 0.33× | 0.51× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
NATL
| Services | $848.0M | 74% |
| APJ | $136.0M | 12% |
| Americas Excluding United States | $135.0M | 12% |
| TT | $44.0M | 4% |
PODD
| Omnipod | $515.6M | 68% |
| International Omnipod | $242.9M | 32% |
| Drug Delivery | $3.3M | 0% |
